patients with malignancies
Conditions
Interventions
Injection of 3.7-5.55MBq/kg F18-BPA and PET/CT imaging study of 4 hours and blood examinations, and conventional F18-FDG PET/CT examination
Sponsors
"Hotta Group" of National Cancer Center Cancer Research and Development Fund
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Written informed consent can be obtained Equal to or over 2 years and less tha 80 years Established diagnosis of malignancy by histology or cytology with evaluable lesions PS is 0-2 Quiet supine position can be kept during PET/CT examinations F18-FDG PET/CT can be performed within 2 weeks of F-18-BPA PET/CT Main organs functions must be normal EKG before F18-BPA injection must be normal
Exclusion criteria
Exclusion criteria: entered or entering to other clinical trials within 3 months Patients with uncontrollable diabetes or hypertension, with phenylketonuria, unstable angina, chronic renal disease or renal failure Patients who cannot undergo F18-FDG PET/CT Pregnant women or women who have the possibility to be pregnant Lactating women Patient who wants the partner be pregnant Patients with mental disorders whose entry to the clinical trial seems diffucult Patients who are considered to be ineligible by referring physician
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Comparison of F18-BPA and F18-FDG PET/CT Comparison and evaluation of F18-BPA accumulations in the target lesions and their clinical characteristics | — |
Primary
| Measure | Time frame |
|---|---|
| Safety of F18-BPA Biodistribution of F18-BPA Optimal imaging conditions of F18-BPA PET/CT | — |
Countries
Japan
Contacts
Public ContactJun ITAMI
National Cancer Center Hospital Department of Radiation Oncology
Outcome results
None listed